Zydus Cadila has introduced an NDDS product ‘Nudoxa’ for the treatment of various
cancers. One of the critical drugs used in chemotherapy, Nudoxa heralds a new approach
in cancer therapy.
With chemotherapy being a common mode of treatment in cancers, there has been a long
standing need for a drug that is stable and long lasting with reduced toxicity and side
effects. Nudoxa addresses this need. A patented product in India and South Africa,
several countries globally.
Doxorubicin, the first generation drug, was launched in 1960s and gave a new lease of
life to cancer patients with its ability to combat aggressive and malignant tumours. This
DNA-interacting drug, however, was discovered to cause life-threatening side effects in
the form of cardiac abnormalities.
An advancement on this therapy resulted in liposomal doxorubicin in which the
molecules of the drug are encapsulated in a fatty coating known as liposomes. The
liposomes allow the doxorubicin to be delivered specifically in greater amounts to the
cancer cells, while having fewer side effects on the healthy tissues. A further
advancement in this line of treatment was the Pegylated-liposomal doxorubicin, a unique
form of liposomal doxorubicin in which the liposomes are coated with polyethylene
glycol, leading to a much longer half-life in the blood. However Pegylated-liposomal
doxorubicin are likely to cause ‘Hand-Foot Syndrome,’ characterized by skin eruptions
on the palms of the hand or soles of the feet, leading to interruption in therapy.
A new variant of liposomal doxorubicin, Nudoxa with its unique drug delivery system is
a breakthrough in cancer therapy as it offers the benefits of Pegylated-liposomal
doxorubicin without its major side effects like the Hand
Foot syndrome. Marketed by Zydus Biogen, Nudoxa is
manufactured by Zydus-BSV Pharma Pvt. Ltd., the joint
venture company of Zydus Cadila and Bharat Serums and
Vaccines Pvt. Ltd. Founded in 2005, Zydus-BSV Pharma
focuses on targeted therapies in the area of Oncology.
Nudoxa is being used as a chemotherapy drug to treat
various cancers, particularly, breast cancer - the second
most common type of cancer, ovarian cancer - the fifthleading
cause of cancer death in women, and AIDS-related
Kaposi sarcoma which develops in people who are infected
with the human immunodeficiency virus (HIV).